J. Tisdale

Safety of liver biopsy in patients with sickle cell related liver disease: A single‐center experience

M. Gladwin, E. Levy, D. Kleiner, 2022, American journal of hematology.

Alemtuzumab clearance, lymphocyte count, and T‐cell chimerism after hematopoietic stem cell transplant in sickle cell disease

Thomas E. Hughes, C. Peer, M. Hsieh, 2021, Pharmacotherapy.

Transduction of hematopoietic stem cells in humans and in nonhuman primates

D. Bodine, T. Soma, J. Zujewski, 1997, Stem cells.

Intracellular interferon- (cid:1) in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia

D. Follmann, J. Maciejewski, E. Sloand, 2002 .

Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.

H. Bitter, P. Gregory, Manfred Schmidt, 2021, The New England journal of medicine.

Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease

Richard L. Frock, R. Bak, Christopher A. Vakulskas, 2021, Science Translational Medicine.

Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity.

R. Bergan, R. Gress, G. Schwartz, 1998, Antisense & nucleic acid drug development.

Longitudinal neurocognitive effects of nonmyeloablative hematopoietic stem cell transplant among older adolescents and adults with sickle cell disease: A description and comparison with sibling donors.

P. Wolters, Staci Martin, C. Fitzhugh, 2023, Neuropsychological rehabilitation.